Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Adverum Biotechnologies (ADVM) has granted inducement awards to 5 new employees under its 2017 Inducement Plan. The awards include:
- Non-qualified stock options to purchase 44,380 shares at $4.20 per share
- Restricted stock units (RSUs) for 22,790 shares
The stock options will vest over 4 years, with 25% vesting after the first year and the remaining vesting monthly over 36 months. The RSUs will vest over 3 years, with one-third vesting annually. Both awards are contingent on continued employment with Adverum. These grants were approved by the Compensation Committee as inducement material for new employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Adverum Biotechnologies (ADVM) ha concesso premi di incentivazione a 5 nuovi dipendenti nell'ambito del suo Piano di Incentivazione del 2017. I premi includono:
- Opzioni su azioni non qualificate per l'acquisto di 44.380 azioni a 4,20 dollari per azione
- Unità di azioni vincolate (RSU) per 22.790 azioni
Le opzioni su azioni matureranno nell'arco di 4 anni, con il 25% che matura dopo il primo anno e il restante che matura mensilmente per 36 mesi. Le RSU matureranno in 3 anni, con un terzo che matura annualmente. Entrambi i premi sono subordinati al mantenimento dell'impiego presso Adverum. Questi premi sono stati approvati dal Comitato per la Compensazione come materiale di incentivazione per nuovi assunti in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
Adverum Biotechnologies (ADVM) ha otorgado premios de incentivo a 5 nuevos empleados bajo su Plan de Incentivo de 2017. Los premios incluyen:
- Opciones sobre acciones no calificadas para la compra de 44,380 acciones a 4.20 dólares por acción
- Unidades de acciones restringidas (RSUs) para 22,790 acciones
Las opciones sobre acciones se consolidarán durante 4 años, con un 25% consolidándose después del primer año y el resto consolidándose mensualmente durante 36 meses. Las RSUs se consolidarán durante 3 años, con un tercio consolidándose anualmente. Ambos premios están condicionados a la continuación del empleo con Adverum. Estos premios fueron aprobados por el Comité de Compensación como material de incentivo para nuevos empleados de acuerdo con la Regla de Cotización de Nasdaq 5635(c)(4).
Adverum Biotechnologies (ADVM)는 2017년 유인 계획에 따라 5명의 신규 직원에게 유인 보상을 부여했습니다. 보상 내용은 다음과 같습니다:
- 주당 4.20달러에 44,380주를 구매할 수 있는 비자격 주식 옵션
- 22,790주에 대한 제한 주식 단위(RSU)
주식 옵션은 4년에 걸쳐 분할 지급되며, 첫 해에 25%가 지급되고 나머지는 36개월 동안 매달 지급됩니다. RSU는 3년에 걸쳐 분할 지급되며, 1/3은 매년 지급됩니다. 두 보상 모두 Adverum에서 계속 근무하는 것에 따라 조건이 달라집니다. 이 보상은 Nasdaq 상장 규칙 5635(c)(4)에 따라 신규 고용을 위한 유인 자료로 보상 위원회에 의해 승인되었습니다.
Adverum Biotechnologies (ADVM) a accordé des primes d'incitation à 5 nouveaux employés dans le cadre de son Plan d'Incitation de 2017. Les primes comprennent :
- Options d'achat d'actions non qualifiées pour l'acquisition de 44 380 actions à 4,20 dollars par action
- Unités d'actions restreintes (RSU) pour 22 790 actions
Les options d'achat d'actions seront acquises sur 4 ans, avec 25 % acquises après la première année et le reste acquis mensuellement pendant 36 mois. Les RSU seront acquises sur 3 ans, avec un tiers acquis annuellement. Les deux primes sont conditionnées à la poursuite de l'emploi chez Adverum. Ces attributions ont été approuvées par le Comité de Rémunération comme matériel d'incitation pour un nouvel emploi conformément à la Règle de Cotation Nasdaq 5635(c)(4).
Adverum Biotechnologies (ADVM) hat im Rahmen seines Anreizplans von 2017 Anreizprämien an 5 neue Mitarbeiter vergeben. Die Prämien umfassen:
- Nicht qualifizierte Aktienoptionen zum Kauf von 44.380 Aktien zu je 4,20 Dollar
- Beschränkte Aktieneinheiten (RSUs) für 22.790 Aktien
Die Aktienoptionen werden über 4 Jahre fällig, wobei 25% nach dem ersten Jahr und der Rest monatlich über 36 Monate fällig wird. Die RSUs werden über 3 Jahre fällig, wobei ein Drittel jährlich fällig wird. Beide Prämien sind an die Fortsetzung der Beschäftigung bei Adverum gebunden. Diese Vergaben wurden vom Vergütungsausschuss als Anreizmaterial für neue Beschäftigungsverhältnisse gemäß der Nasdaq-Listing-Regel 5635(c)(4) genehmigt.
- None.
- None.
REDWOOD CITY, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 44,380 shares of common stock and restricted stock units (RSUs) for 22,790 shares of common stock to 5 new employees under Adverum’s 2017 Inducement Plan. The Compensation Committee of Adverum’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option has an exercise price per share equal to
About Adverum Biotechnologies
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy to preserve sight for life in highly prevalent ocular diseases with the aspirations of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit www.adverum.com.
Inquiries:
Adverum Investor Relations
Email: ir@adverum.com
FAQ
What inducement awards did Adverum Biotechnologies (ADVM) grant to new employees in February 2025?
What is the vesting schedule for ADVM's February 2025 stock option grants?
How will the RSUs vest in Adverum's February 2025 inducement grants?
What was the exercise price for ADVM's February 2025 inducement stock options?
